DiaMedica Therapeutics (DMAC) Profit After Tax (2018 - 2026)

DiaMedica Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at -$10.0 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 30.3% year-over-year to -$10.0 million in Q1 2026; TTM through Mar 2026 was -$35.1 million, a 30.71% decrease from a year earlier, with the FY2025 full-year figure at -$32.8 million, down 34.28% from the prior year.
• Profit After Tax eased to -$10.0 million in Q1 2026 per DMAC's latest filing, from -$8.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$3.1 million in Q3 2022 and bottomed at -$10.0 million in Q1 2026.
• The 5-year median for Profit After Tax is -$5.2 million (2024), against an average of -$5.9 million.
• Across the five-year window, Profit After Tax grew 11.48% in 2022 and plunged 56.78% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$3.8 million in 2022, then sank by 34.04% to -$5.0 million in 2023, then tumbled by 56.78% to -$7.9 million in 2024, then slipped by 11.65% to -$8.8 million in 2025, then decreased by 14.1% to -$10.0 million in 2026.
• Per Business Quant, the three latest DMAC Profit After Tax figures stand at -$10.0 million (Q1 2026), -$8.8 million (Q4 2025), and -$8.6 million (Q3 2025).